Liver News and Research

RSS

Piramal to present data on several molecular imaging compounds at SNM annual meeting

Piramal Imaging SA, a subsidiary of Piramal Healthcare Limited, will present data on several compounds from its molecular imaging portfolio at the Society of Nuclear Medicine's 59th annual meeting in Miami Beach, Fla., from June 9 - 13.

10 Jun 2012

Vitamin A supplements may reduce skin cancer risk

Taking vitamin A supplements reduces the risk for developing a deadly form of skin cancer called melanoma, say US researchers.

8 Jun 2012

Nonin Medical releases EQUANOX Advance Model 8004CB Series neonatal/pediatric sensor

Nonin Medical, Inc. announced today the U.S. market release of its EQUANOX Advance Model 8004CB Series neonatal/pediatric sensor.

8 Jun 2012

What are vitamins?

Most people have heard of vitamin C and its effects upon the body; but how much do you know about other vitamins? How many even are there? And what do they all do?

8 Jun 2012

Scientists uncover origin of Langerhans cells

Scientists at A*STAR's Singapore Immunology Network (SIgN) uncovered the origin of a group of skin-deep immune cells that act as the first line of defence against harmful germs and skin infections. SIgN scientists discovered that these sentry cells of the skin, called the Langerhans cells (LCs), originate from two distinct embryonic sites - the early yolk sac and the foetal liver.

8 Jun 2012

Study identifies molecular changes responsible for abnormal cholesterol production and metabolism

A new study from the Virginia Commonwealth University School of Medicine has identified molecular changes responsible for abnormal cholesterol production and metabolism in the livers of patients with a common liver condition, and these changes may explain the severity of a patient's liver disease and risks to their heart health.

8 Jun 2012

Successful pregnancies common for female liver transplant recipients

New research confirms that successful pregnancies are common for female liver transplant recipients. The study appearing in the June issue of Liver Transplantation, a journal published by Wiley-Blackwell on behalf of the American Association for the Study of Liver Diseases, found miscarriage risk was lower and the live birth rate higher among women following liver transplantation than in the general U.S. population.

7 Jun 2012

CDI introduces MyCell Services

Cellular Dynamics International, Inc. (CDI), the world's largest commercial producer of human induced pluripotent stem (iPS) cell lines and tissue cells, today announced the launch of its MyCell Services.

7 Jun 2012

Studies evaluate transplantation potential and success of islet cells derived from pancreatic tissues

Two studies appearing in the current issue of Cell Transplantation, evaluate the transplantation potential and success of islet cells derived from pancreatic tissues, in addition to a clinical study that reports the occurrence of adverse events.

7 Jun 2012

ProFibrix initiates Phase III trial with Fibrocaps in spine, liver, vascular and soft tissue surgery

ProFibrix B.V., a leader in the development of innovative bioactive products to stop bleeding (hemostasis), today announced the start of its pivotal Phase III clinical trial with Fibrocaps (FINISH-3) in spine, liver, vascular and soft tissue surgery.

7 Jun 2012

Arrowhead initiates final IND-enabling steps for ARC-520 to treat HBV

Arrowhead Research Corporation, a targeted therapeutics company, today announced that its hepatitis B virus (HBV) program has completed all internal preclinical requirements and has named a clinical candidate.

7 Jun 2012

Ancient hepatitis B may hold clues to viral evolution, spread

The evolution of the hepatitis B virus and its possible migration have become clearer with the sequencing of the oldest sample of the virus, isolated from a mummified 16th-century Korean child, say scientists.

6 Jun 2012

Infants, children ‘susceptible to acetaminophen overdose’

Acute acetaminophen overdose is the most common identifiable cause of acute liver failure in children, warn researchers in the Canadian Medical Association Journal.

6 Jun 2012

STELARA effectively reduces signs and symptoms of active psoriatic arthritis

Patients with active psoriatic arthritis receiving the interleukin (IL)-12/23 inhibitor STELARA (ustekinumab) experienced significant improvements in signs and symptoms of the disease, according to new findings presented today from a Janssen Research & Development, LLC, (Janssen)-sponsored investigational study.

6 Jun 2012

Patients with type 2 diabetes have 20% increased risk of blood cancers

Patients with type 2 diabetes have a 20 percent increased risk of developing blood cancers, such as non-Hodgkin lymphoma, leukemia and myeloma, according to a new meta-analysis led by researchers at The Miriam Hospital.

6 Jun 2012

Positive updated interim data from Exelixis’ cabozantinib phase 2 trial on CRPC

Exelixis, Inc. today reported positive updated interim data from an ongoing phase 2 trial of cabozantinib in men with metastatic castration-resistant prostate cancer (CRPC) and bone metastases.

6 Jun 2012

T-DM1 better than standard therapy in controlling breast cancer

A new cancer treatment that links chemotherapy with an agent that homes in on specific breast cancer cells was significantly better than the current drug regimen at keeping patients' advanced tumors from progressing, according to results from a Phase III clinical trial led by Kimberly Blackwell, M.D., of the Duke Cancer Institute.

5 Jun 2012

Investigational diabetes drug appears to improve insulin sensitivity without side effects

Drugs for type 2 diabetes can contribute to weight gain, bone fractures and cardiovascular problems, but in mice, an investigational drug appears to improve insulin sensitivity without those troublesome side effects, researchers at Washington University School of Medicine in St. Louis have shown.

5 Jun 2012

Jennerex announces data from JX-594 clinical studies on cancer

Jennerex, Inc., a private clinical-stage biotherapeutics company focused on the development and commercialization of first-in-class targeted oncolytic virus products for cancer, today announced that data relating to the company's oncolytic virus therapy for cancer was featured in three separate abstracts during the American Society of Clinical Oncology (ASCO) Annual Meeting currently taking place in Chicago, Illinois.

5 Jun 2012

Ipsen, Active Biotech present OS data from tasquinimod Phase II study on CRPC at ASCO 2012

Active Biotech and Ipsen today presented overall survival (OS) data from the tasquinimod Phase II study in chemotherapy-naïve metastatic castrate resistant prostate cancer (CRPC) at the scientific conference "2012 ASCO Annual Meeting" held in Chicago (USA).

5 Jun 2012